organon dermavant news

Organon, Roivant

Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis

Organon acquires ROIV's Dermavant for $1.2B, expanding their dermatology portfolio and potentially increasing sales. Click here to read my most recent analysis.

NJBIZ · 4d

Organon to acquire Dermavant in $1.2B deal

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

GlobalData on MSN · 4d

Organon makes $1.2bn play for Roivant’s immuno-dermatology subsidiary

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis.

The Pharma Letter · 5d

Organon to acquire Dermavant in back-loaded deal

Women’s health specialist Organon has entered into a definitive agreement to acquire Dermavant Sciences, a Roivant company.

Reuters · 5d

Organon to buy Roivant's dermatology unit for up to $1.2 billion

Shares of Roivant, which owns 86% of Dermavant as of March 31, 2024, and was founded by former Republican presidential candidate Vivek Ramaswamy, were up 1.7% at $12.26 in early trading. However, Organon was down 1.4%. Dermavant's Vtama cream, approved by ...

MarketWatch · 5d

Organon to Buy Roivant's Dermavant Unit in Deal Worth Up to $1.2 Billion

Organon has agreed to buy medical dermatology company Dermavant Sciences, a majority-owned unit of Roivant Sciences, in a deal worth up to $1.2 billion. Organon on Wednesday said it will make an up-front payment of $175 million,

FiercePharma5d

Organon pays up to $1.2B to acquire Dermavant and its steroid-free skin cream Vtama

Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies ...

pharmaphorum4d

Organon makes dermatology play with $1.2bn Dermavant buyout

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

5don MSN

Roivant Flips a Skin Drug to Organon

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

5don MSN

Organon to buy skin therapy developer Dermavant for up to $1.2 billion

(Reuters) -Healthcare company Organon said on Wednesday it has agreed to acquire skin therapy developer Dermavant, a unit of Roivant, for up to $1.2 billion. Organon will make an upfront payment of ...

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Organon: A Surprising Deal

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results